Who Should Attend
Those who would benefit most include CEOs and senior executives of biotech companies involved in company development and strategic planning; venture capitalists involved in biotech company development; business development executives assessing possible partnerships or acquiring biotechnology companies; consultants entering the biotechnology arena; and equity investors who evaluate biotech companies.
Special study groups, pricing, and other arrangements are available to companies sponsoring teams of four or more participants. Please contact us to learn more.
|
